Clinical & Experimental Metastasis

, Volume 13, Issue 1, pp 49–56 | Cite as

Overexpression and localization of cathepsin B during the progression of human gliomas

  • Marupudi Sivaparvathi
  • Raymond Sawaya
  • Shang Wu Wang
  • Alan Rayford
  • Masaaki Yamamoto
  • Lance A. Liottat
  • Garth L. Nicolson
  • Jasti S. Rao
Research Papers


Degradation of the extracellular matrix is a prerequisite for acquisition of the invasive phenotype. Several proteinases released by invading tumor cells appear to participate in the focal degradation of extracellular matrix proteins. Using an enzyme-linked immunosorbent assay, enzymatic assays, Western and Nothern blotting techniques, we determined whether increased levels of the cysteine protease cathepsin B correlated with the progression and invasion of human gliomas. The amount of cathepsin B activity and protein content were highest in glioblastomas, lower in anaplastic astrocytomas and lowest in normal brain tissue and low-grade gliomas. There were significantly higher amounts of Mr 25 000 and 26 000 bands in glioblastoma and anaplastic astrocytoma than in normal brain and low-grade glioma tissue extracts as determined by Western blotting with anti-cathepsin antibodies. In addition, cathepsin B transcripts were overexpressed in anaplastic astrocytoma (about two- to three-fold), in glioblastoma (about eight- to 10-fold), compared with normal brain tissue and low-grade glioma. Immunobistochemical staining for cathepsin B showed intense immunoreactivity in tumor and endothelial cells of glioblastomas and anaplastic astrocytomas but only weak immunoreactivity in low-grade glioma and normal brain tissues. Therefore, we conclude that cathepsin B expression is greatest in highly malignant astrocytomas, especially in glioblastomas, and is correlated with the malignant progression of astrocytomas.


cysteine proteases extracellular matrix glioblastoma multiforme invasion 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Russel DE and Rubinstein LJ, 1989, Pathology of the tumors of the nervous system. London: Edward Arnold (ed.) 5th ed.Google Scholar
  2. 2.
    Gleave JRW, 1986, Surgery for primary brain tumors. In: N. M. Bleehen (ed.), Tumors of the Brain, pp. 101–20. Berlin: Springer-Verlag.Google Scholar
  3. 3.
    Sheline GE, 1986, Normal tissue tolerance and radiation therapy of gliomas of the adult brain. In: N. M. Bleehen (ed.), Tumors of the Brain, pp. 83–99. Berlin: Springer Verlag.Google Scholar
  4. 4.
    Workman P, 1986, The pharmacology of brain tumor chemotherapy. In: N. M. Bleehen (ed.). Tumors of the Brain, pp. 183–200. Berlin: Springer-Verlag.Google Scholar
  5. 5.
    Rutka JT, Myatt CA, Giblin JR, Davis RL and Rosenblum ML, 1987, Distribution of extracellular matrix proteins in primary human brain tumors: an immunohistochemical analysis. Can J Neurol Sci, 14, 25–30.Google Scholar
  6. 6.
    Dane K, Andreasen PA, Grondahl-Hansen J, et al. 1985, Plasminogen activators, tissue degradation and cancer. Adv Cancer Res, 44, 139–266.Google Scholar
  7. 7.
    Sloane BF, Honn KV, Sadler, JG et al., 1982, Cathepsin B activity in B16 melanoma cells: a possible marker for metastatic potential. Cancer Res, 42, 980–6.Google Scholar
  8. 8.
    Eckhout Y and Vaes G, 1977, Further studies on the activation of procollagenase, the latent precursor of bone collagenase: effect of lysosomal cathepsin B, plasmin, and kallikrein and spontaneous activation. Biochem J, 166, 21–31.Google Scholar
  9. 9.
    Kobayashi H, Schmitt M, Goretzki L, et al. 1991, Cathepsin B efficiently activates the soluble and tumor cell receptor bound form of the proenzyme urokinasetype plasminogen activator (pro uPA). J Biol Chem, 266, 5147–52.Google Scholar
  10. 10.
    Recklies AD, Tiltman KJ, Stoker AM and Poole RA, 1980, Secretionof proteinases from malignant and non-malignant human breast tissue. Cancer Res, 40, 550–6.Google Scholar
  11. 11.
    Keppler D, Fondaneche MC, Dalet-Fumeron V, Pagano M and Burtin P, 1988, Immunohistochemical and biochemical study of a cathepsin B-like proteinase in human colonic cancers. Cancer Res, 48, 6855–62.Google Scholar
  12. 12.
    McCormick D, 1993, Secretion of cathepsin B by human gliomas in vitro. Neuropathol Appl Neurobiol, 19, 146–51.Google Scholar
  13. 13.
    Bradford MM, 1976, A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem, 72, 248–56.Google Scholar
  14. 14.
    Barrett AJ and Kirschke H, 1981, Cathepsin B, cathepsin H and cathepsin L. Methods Enzymol, 80, 535–61.Google Scholar
  15. 15.
    Towbin H, Staehlin T and Grodon J, 1979, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and applications. Proc Natl Acad Sci USA, 76, 4350–4.Google Scholar
  16. 16.
    Chomczynski P and Sacchi N, 1987, Single step method of RNA isolation by acid guanidinium thiocyanate phenolchloroform extraction. Anal Biochem, 162, 156–9.Google Scholar
  17. 17.
    Chan MM-Y and Fong D, 1988, Expression of human cathepsin B protein in Eschericia coli. FEBS Lett, 239, 219–22.Google Scholar
  18. 18.
    Cao L, Taggart RT, Berquin IM, et al. 1994, Human gastric adenocarcinoma cathepsin B: isolation and sequencing of full-length cDNAs and polymorphisms of the gene. Gene, 139, 163–9.Google Scholar
  19. 19.
    Gross JR, Behrens DL, Mullins DE, Kornbligh PL and Dexter DL 1988, Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate. Cancer Res, 48, 291–6.Google Scholar
  20. 20.
    Sawaya R, Ramo OJ, Shi ML and Mandybur G, 1991, Biological significance of tissue plasminogen activator content in brain tumors. J Neurosurg, 74, 480–6.Google Scholar
  21. 21.
    Yamamoto M, Sawaya R, Mohanam S, et al. 1994, Expression and localization of urokinase-type plasminogen activator in human astrocytoma in vivo. Cancer Res, 54, 3656–61.Google Scholar
  22. 22.
    Rao JS, Steck PA, Kono S, et al. 1994, Role of plasminogen activators and of 92-kDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. J Neuro-Oncol, 18, 129–38.Google Scholar
  23. 23.
    Apodaca G, Rutka JT, Bouhana K, et al. 1990, Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res, 50, 2322–9.Google Scholar
  24. 24.
    Lund-Johansen M, Rucklidge GJ, Milne G and Bjerkvig R, 1991, A metalloproteinase capable of destroying cultured brain tissue isolated from rat glioma cells. Anticancer Res, 11, 1001–6.Google Scholar
  25. 25.
    Reith A and Ricklidge GJ, 1992, Invasion of brain tissue by primary glioma: evidence for the involvement of urokinase-type plasminogen activator as an activator of the type IV collagenase. Biochem Biophys Res Commun, 186, 348–54.Google Scholar
  26. 26.
    Caroni P and Schwab ME, 1988, Two membrane protein fractions from rat central myelin with inhibitory properties for neurite growth and fibroblast spreading. J Cell Biol, 106, 1281–8.Google Scholar
  27. 27.
    Rao JS, Steck PA, Mohanam S, et al. Elevated levels of Mr 92 000 type IV collagenase in human brain tumors. Cancer Res, 53, 2208-11.Google Scholar
  28. 28.
    McDonald JK and Ellis S, 1975, On the substrate specificity of cathepsin B1 and B2 including a new fluorogenic substrate for cathepsin B. Life Sci, 17, 1269–76.Google Scholar
  29. 29.
    Olstein AD and Liener IE, 1983, Comparative studies of mouse liver cathepsin B and an analogous tumor thiol proteinase. J Biol Chem, 258, 11049–56.Google Scholar
  30. 30.
    Home WH, Glossl J and Kresse H, 1987, Biosynthesis of cathepsin B in cultured normal and I-cell fibroblasts. J Biol Chem, 262, 12351–5.Google Scholar
  31. 31.
    Chan SJ, San Segundo B, McCormick MB and Steiner DF, 1986, Nucleotide and predicted amino acid sequences of cloned human and mouse preprocathepsin B cDNAs. Proc Natl Acad Sci USA, 83, 7721–5.Google Scholar
  32. 32.
    Nishimura Y, Kawabata T and Kato K, 1988, Identification of latent procathepsins B and L in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Arch Biochem Biophys, 261, 64–71.Google Scholar
  33. 33.
    Keren Z and Le Grue SJ, 1988, Identification of cell surface cathepsin B-like activity on murine melanomas and fibrosarcomas: modulation of butanol extraction. Cancer Res, 48, 1416–21.Google Scholar
  34. 34.
    Rozhien J, Robinson D, Stevens MA, et al. 1987, Properties of a plasma membrane-associated cathepsin B-like cystein proteinase in metastatic B16 melanoma variants. Cancer Res, 47, 6620–8.Google Scholar

Copyright information

© Rapid Communications of Oxford Ltd 1995

Authors and Affiliations

  • Marupudi Sivaparvathi
    • 1
  • Raymond Sawaya
    • 1
  • Shang Wu Wang
    • 1
  • Alan Rayford
    • 1
  • Masaaki Yamamoto
    • 1
  • Lance A. Liottat
    • 3
  • Garth L. Nicolson
    • 2
  • Jasti S. Rao
    • 1
  1. 1.Department of NeurosurgeryThe University of Texas M. D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of Tumor BiologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA
  3. 3.Laboratory of PathologyNCIBethesdaUSA

Personalised recommendations